Peptifact

Tesamorelin for Men: The Trials Were Mostly Men — What That Record Shows, and What It Does Not

Men were 84–90% of participants in every phase of the trials behind Egrifta, and the only tesamorelin trial restricted to one sex enrolled men. What those studies measured in men — visceral fat, IGF-1, glucose, liver fat — what the label says that bears on men, and the questions men ask that no trial has answered.

Robert F · Edited by Caroline S · Published 2026-11-19

Illustration: An open insulated shipping box with foam inserts and an empty clear glass vial on a cool grey surface.
Illustration

Tesamorelin is the drug in Egrifta, a growth-hormone-releasing-hormone analogue approved to reduce belly fat in adults with HIV. Men search for it because clinics advertise it to them for visceral fat, body composition and "anti-ageing". The question here is narrow: what the published record shows in men, and where it stops.

The answer is the reverse of the women's question. Our tesamorelin for women page found that women were too few in the trials for a separate result. For men the problem is different: almost the whole record is men, but men with HIV, on one endpoint, for at most a year. The overall trial findings — the 26-week visceral-fat drop, what happened after stopping, who did not respond — are on our tesamorelin results page, and the harms on our tesamorelin side effects page. For a plain explanation of the molecule, see Peptide Lexicon's tesamorelin entry. Nothing here is a recommendation.

The approval record is a record in men

The Egrifta WR label (Theratechnologies, DailyMed, effective 29 July 2026, read 19 November 2026) describes four trial phases. Every participant had HIV and lipodystrophy, and men had a waist of at least 95 cm and a waist-to-hip ratio of at least 0.94 to enter.

Trial phase (label) Participants Men Men, approximate (our arithmetic)
Study 1, 26-week main phase 410 86% ~353
Study 2, 26-week main phase 396 84% ~333
Study 1 extension, re-randomised 204 88% ~180
Study 2 extension, re-randomised 177 90% ~159

Mean weight at entry was 88–90 kg and mean waist 102–105 cm. So the label's figures — visceral fat down 18% against +2% on placebo in study 1 and 14% against −2% in study 2 — are, in practice, results in middle-aged men with HIV and central fat. The first published trial (Falutz 2007, NEJM, PMID 18057338) reported visceral fat −15.2% against +5.0%, IGF-1 up 81%, and triglycerides down 50 mg/dL, in a population that was 86% men.

What the label does not support is the step clinics take next: from men with HIV to men without it. The indication is HIV-associated lipodystrophy, and the label adds that Egrifta WR "is not indicated for weight loss management".

Studies in men without HIV

Three study reports, from one Boston group, are the published record in men without HIV:

Study Who Length What was measured What it found
Stanley 2011, JCEM (PMID 20943777; NCT00850564) 13 healthy men, mean age 45, BMI 27 2 weeks, 2 mg a day Overnight GH pulses, IGF-1, insulin sensitivity by clamp IGF-1 +181 ± 22 µg/L; GH pulses larger; fasting glucose and insulin-stimulated glucose uptake not significantly changed
Makimura 2011, Growth Horm IGF Res (PMID 21531600) Same 13 men 2 weeks Adiponectin No significant change in total or high-molecular-weight adiponectin
Makimura 2012, JCEM (PMID 23015655) 60 obese adults with reduced GH secretion; 39 men 12 months, 2 mg a day, placebo-controlled Visceral fat by CT, carotid intima-media thickness, triglycerides, glucose Visceral fat −16 cm² v +19 cm² on placebo (effect −35 cm²); triglycerides and CRP down; carotid thickness −0.04 mm; no change in glucose or HbA1c

The 2012 trial is the strongest evidence that tesamorelin reduces visceral fat outside HIV, and two-thirds of its participants were men (20 of 31 on tesamorelin, 19 of 29 on placebo, from its baseline table). It did not report results by sex, enrolled only people with measurably reduced growth hormone secretion, and stopped at 12 months. A 39-person analysis from a 12-month trial by the Massachusetts General Hospital team linked the IGF-1 rise to faster phosphocreatine recovery after exercise, a marker of muscle energy metabolism (Makimura 2014, PMID 24178787); it was not a strength or performance measure.

ClinicalTrials.gov, read on 19 November 2026, lists 24 studies of tesamorelin. Twenty-three accept both sexes; NCT00850564, the 15-man study above, is the only one restricted to men. None registers testosterone, libido or athletic performance as its main question. The nearest is NCT06554717, recruiting since July 2025, which tests tesamorelin alongside exercise in about 100 people with HIV, with chair-stand time over 24 weeks as its primary outcome; it has no results yet.

What men ask that the record does not answer

  • Muscle and physique. No trial tested tesamorelin for muscle growth. A secondary CT analysis of responders in the HIV trials (Adrian 2019, PMID 31237318; 87% men) found small rises in trunk-muscle area — about 0.44 cm² in the rectus and 0.46 cm² in the psoas over 26 weeks — and lower muscle fat. A second analysis of the same scans found visceral and subcutaneous fat became denser (Lake 2021, PMID 33756511). Both were exploratory, restricted to people whose visceral fat had already fallen, and measured scans, not strength.
  • Testosterone. No tesamorelin study read for this page reports testosterone as an outcome. The healthy-men study excluded anyone who had used testosterone or other steroids in the previous six months, so it says nothing about the combination.
  • Ageing men. A 2013 review of growth hormone in ageing men (Sattler, PMID 24054930) reviewed the potential of GH augmentation with an emphasis on men, because women "appear more resistant to treatment"; it is a review, not a tesamorelin trial in older men.
  • Long-term safety. The label states that long-term cardiovascular safety has not been established. The longest controlled exposure in men without HIV is 12 months.

What the label says that bears on men

The label has no male-specific warning, but three passages matter to the men most likely to be using it:

  • Other medicines. It states that growth hormone may alter the clearance of drugs metabolised by CYP450 liver enzymes — naming corticosteroids, sex steroids, anticonvulsants and cyclosporine — and advises monitoring when tesamorelin is combined with them. Testosterone is a sex steroid; the label reports no study of the combination.
  • Glucose. It warns that glucose intolerance or diabetes may develop and that glucose should be evaluated before and during therapy; in the trials, HbA1c of 6.5% or more by week 26 occurred in 5% on tesamorelin and 1% on placebo. In the healthy-men study, glucose did not change significantly over two weeks; that is a short window.
  • Fertility. In rats, tesamorelin had no effect on male fertility at doses about equal to clinical exposure for 28 days. There are no human fertility data in the label.

The label's dose for Egrifta WR is 1.28 mg once a day under the skin of the abdomen; the older studies above used 2 mg a day of an earlier formulation, and the label states the two current formulations are not substitutable. These are the label's and the trials' figures, reported for context, not guidance.

Reports to the FDA

An openFDA count of the FDA Adverse Event Reporting System (data to 28 October 2026, read 19 November 2026) returned 1,692 reports naming tesamorelin. Where sex was recorded, 450 were men and 77 women — about six to one, roughly the trials' own ratio. FAERS reports are unverified and do not show that the drug caused an event; the count mostly reflects who receives it.

The short version

For men, tesamorelin's evidence is broad in one direction and absent in the others. It reliably raised IGF-1 and cut visceral fat in men with HIV, and cut visceral fat in one 12-month trial of obese men and women with low growth hormone. It was never tested for muscle, strength, testosterone or performance, and its long-term cardiovascular safety is not established. Whether it suits any one man is a question for a prescriber, outside an approval that covers HIV only. How it compares with other growth-hormone secretagogues is on our CJC-1295 vs tesamorelin and tesamorelin vs ipamorelin pages; MuscleLedger covers it for training readers on its tesamorelin compound page.

Sources

  • Egrifta WR prescribing information (Theratechnologies), DailyMed set 839334d3-8c1d-4c26-9036-2ab524a6ea75, via openFDA labels, effective 29 July 2026; Egrifta SV label, set 3d783378, same date; read 19 November 2026.
  • Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359–70. PMID 18057338 (abstract).
  • Stanley TL et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011;96:150–8. PMID 20943777 (abstract).
  • Makimura H et al. Relationship of adiponectin to endogenous GH pulse secretion parameters… Growth Horm IGF Res 2011;21:155–9. PMID 21531600 (abstract).
  • Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion. J Clin Endocrinol Metab 2012;97:4769–79. PMID 23015655 (abstract and PMC3513535 baseline table).
  • Makimura H et al. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab 2014;99:338–43. PMID 24178787 (abstract).
  • Adrian S et al. J Frailty Aging 2019;8:154–9. PMID 31237318; Lake JE et al. AIDS 2021;35:1395–402. PMID 33756511 (abstracts).
  • Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab 2013;27:541–55. PMID 24054930 (abstract).
  • ClinicalTrials.gov API v2, intervention "tesamorelin" (24 studies), and record NCT00850564; read 19 November 2026.
  • openFDA drug adverse event endpoint, tesamorelin, count by patient sex (data to 28 October 2026); read 19 November 2026.

Frequently asked questions

Does tesamorelin work for men?

In the population it was tested in, yes on its measured endpoint: the trials behind its approval were 84–86% men, all with HIV and excess abdominal fat, and visceral fat fell about 14–18% over 26 weeks against little change on placebo. For men without HIV, one 12-month trial in obese adults with reduced growth hormone (39 of 60 were men) found visceral fat fell. Neither trial measured muscle, strength or physique.

Is tesamorelin approved for men without HIV?

No. Egrifta WR and Egrifta SV are approved only to reduce excess abdominal fat in adults with HIV and lipodystrophy, and the label states it is not indicated for weight loss management. Any use in men without HIV is outside the approved indication.

Does tesamorelin raise testosterone?

No published tesamorelin trial read for this page reports testosterone as an outcome, and the label gives no testosterone data. The label does say growth hormone may change how the liver clears sex steroids and other CYP450-metabolised drugs, and advises monitoring when they are combined.

Does tesamorelin build muscle in men?

It was never tested for that. The nearest data are a secondary CT analysis of responders in the HIV trials, 87% men, which found small increases in trunk-muscle area and density (for example about 0.4–0.5 cm² in the rectus and psoas) over 26 weeks; those were exploratory measurements on a scan, not strength or performance.

What about tesamorelin for women?

Women were a minority in every trial, about one participant in seven, and their results were never published separately. That record, the women's entry thresholds and the pregnancy contraindication are on our tesamorelin for women page.